Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
730
Employees730
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
730
Employees730

CORT Key Statistics

Market cap
12.22B
Market cap12.22B
Price-Earnings ratio
280.64
Price-Earnings ratio280.64
Dividend yield
Dividend yield
Average volume
2.62M
Average volume2.62M
High today
$118.79
High today$118.79
Low today
$112.05
Low today$112.05
Open price
$117.33
Open price$117.33
Volume
410.91K
Volume410.91K
52 Week high
$126.38
52 Week high$126.38
52 Week low
$28.66
52 Week low$28.66

Stock Snapshot

With a market cap of 12.22B, Corcept Therapeutics(CORT) trades at $113.09. The stock has a price-to-earnings ratio of 280.64.

As of 2026-09-23, Corcept Therapeutics(CORT) stock has fluctuated between $112.05 and $118.79. The current price stands at $113.09, placing the stock +0.9% above today's low and -4.8% off the high.

Corcept Therapeutics(CORT) shares are trading with a volume of 410.91K, against a daily average of 2.62M.

In the last year, Corcept Therapeutics(CORT) shares hit a 52-week high of $126.38 and a 52-week low of $28.66.

In the last year, Corcept Therapeutics(CORT) shares hit a 52-week high of $126.38 and a 52-week low of $28.66.

CORT News

TipRanks 7h
Corcept Therapeutics Announces New Endocrinology Division President

Corcept Therapeutics ( (CORT) ) has shared an announcement. On September 22, 2026, Corcept Therapeutics said Sean Maduck, president of its Endocrinology divisi...

TipRanks 7h
Corcept Therapeutics president of endocrinology Sean Maduck to retire

Corcept Therapeutics (CORT) announced the retirement of Sean Maduck, President of the company’s Endocrinology division. Justin Gunn will succeed Mr. Maduck and...

Simply Wall St 5d
Corcept Therapeutics Dropped, So What Is Behind The Latest Attention?

Corcept Therapeutics (CORT) is back in focus after regulators in Europe moved its lead oncology asset a step closer to potential approval for platinum-resistant...

Corcept Therapeutics Dropped, So What Is Behind The Latest Attention?

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
14.3%
Sell
14.3%

More CORT News

TipRanks 5d
Corcept announces positive CHMP opinion for Lifyorli

Corcept Therapeutics (CORT) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that the European Comm...

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.